Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 46, 2016 - Issue 10
Submit an article Journal homepage
986
Views
24
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans

Donghui CuiDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
,
Tamara CabaluDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA, Correspondence[email protected]
,
Ka Lai YeeDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
,
James SmallStructure Elucidation NMR Group, Process Chemistry, Merck & Co, Inc, West Point, PA, USA,
,
Xiaodong LiBristol-Myers Squibb, Full Development Statistics, Global Biometrics Science, Hopewell, NJ, USA, and
,
Bo LiuDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
,
Cheri MaciolekDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
,
Sheri SmithDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
,
Wen LiuDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
,
Jacqueline B. McCreaDepartment of Clinical Pharmacology and Experimental Therapeutics (CPET), Merck & Co, Inc, Kenilworth, NJ, USA
&
Thomayant PrueksaritanontDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co, Inc, West Point, PA, USA,
show all
Pages 882-895 | Received 22 Oct 2015, Accepted 05 Dec 2015, Published online: 10 Feb 2016

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Clemens Muehlan, Cedric Vaillant, Isabelle Zenklusen, Stephan Kraehenbuehl & Jasper Dingemanse. (2020) Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 16:11, pages 1063-1078.
Read now
Jessica L Norman & Sarah L Anderson. (2016) Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant. Nature and Science of Sleep 8, pages 239-247.
Read now

Articles from other publishers (22)

Mohammed H. Alqarni, Muzaffar Iqbal, Ahmed I. Foudah, Tariq M. Aljarba, Fatma Abdel Bar, Sultan Alshehri, Faiyaz Shakeel & Prawez Alam. (2023) Quantification of Suvorexant in Human Urine Using a Validated HPTLC Bioanalytical Method. ACS Omega 8:42, pages 39928-39935.
Crossref
Kenya Watanabe, Shingen Misaka, Keiko Kanno‐Nozaki, Takaaki Chiyoda, Yuhei Suzuki, Akiko Sato, Takahiro Suto, Junko Kuroda, Kenju Shimomura, Itaru Miura & Hirooki Yabe. (2023) Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4. British Journal of Clinical Pharmacology.
Crossref
Andrew H. Han, Caroline R. Burroughs, Evan P. Falgoust, Jamal Hasoon, Grace Hunt, Juyeon Kakazu, Tim Lee, Adam M. Kaye, Alan D. Kaye & Latha Ganti. (2023) Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia. Health Psychology Research 10:5.
Crossref
A.W. Jones, F. Musshoff, T. Krämer, A. E. Steuer, D. Gerostamoulos, O.H. Drummer, G. Drasch, M. Balikova, J. Beyer, H. Teixeira, M. Thevis, W. Schänzer, H. Druid & G. Skopp. 2022. Handbook of Forensic Medicine. Handbook of Forensic Medicine 1167 1312 .
Martine Gehin, Jolanta Wierdak, Giancarlo Sabattini, Patricia N. Sidharta & Jasper Dingemanse. (2021) Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. British Journal of Clinical Pharmacology 88:2, pages 810-819.
Crossref
Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline & Larisa Reyderman. (2021) Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacology Research & Perspectives 9:2.
Crossref
Britni Skillman & Sarah Kerrigan. (2020) CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Science International 312, pages 110307.
Crossref
Nagaraju Rajana, Dharamasoth Rama Devi, Dinne Naresh Kumar Reddy, J Moses Babu, K Basavaiah & K Balakumaran. (2020) Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC. Journal of Chromatographic Science 58:5, pages 433-444.
Crossref
Jason M. Uslaner, William J. Herring & Paul J. Coleman. (2020) The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacology & Translational Science 3:1, pages 161-168.
Crossref
Lee K. Brown & Mark L. Unruh. 2020. Chronic Renal Disease. Chronic Renal Disease 571 592 .
Younggi Choi & Brian K. Raymer. (2019) Sleep modulating agents. Bioorganic & Medicinal Chemistry Letters 29:16, pages 2025-2033.
Crossref
Clemens Muehlan, Hartmut Fischer, Dieter Zimmer, Hamed Aissaoui, Julien Grimont, Christoph Boss, Marie Croft, Joop van Gerven, Stephan Krähenbühl & Jasper Dingemanse. (2019) Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry. Current Drug Metabolism 20:4, pages 254-265.
Crossref
Rebecca E. Wrishko, Jacqueline B. McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco, Eric Mangin, Manu Chakravarthy, Maria P. Martinez-Cantarin & Walter K. Kraft. (2019) Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clinical Drug Investigation 39:5, pages 441-451.
Crossref
W. Joseph Herring, Thomas Roth, Andrew D. Krystal & David Michelson. (2018) Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. Journal of Sleep Research 28:2.
Crossref
Muzaffar Iqbal, Essam Ezzeldin, Nasr Y. Khalil, Prawez Alam & Khalid A. Al-Rashood. (2019) UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets. Journal of Pharmaceutical and Biomedical Analysis 164, pages 1-8.
Crossref
Marie-Laure Boof, Abir Alatrach, Mike Ufer & Jasper Dingemanse. (2018) Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. European Journal of Clinical Pharmacology 75:2, pages 195-205.
Crossref
Ka Lai Yee, Jacqueline McCrea, Deborah Panebianco, Wen Liu, Nicole Lewis, Tamara Cabalu, Steven Ramael & Rebecca E. Wrishko. (2018) Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clinical Drug Investigation 38:7, pages 631-638.
Crossref
Brian Waters, Kenji Hara, Natsuki Ikematsu, Mio Takayama, Aya Matsusue, Masayuki Kashiwagi & Shin-ichi Kubo. (2018) Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases. Journal of Analytical Toxicology 42:4, pages 276-283.
Crossref
Hans-Peter Landolt, Sebastian C. Holst & Amandine Valomon. 2019. Sleep-Wake Neurobiology and Pharmacology. Sleep-Wake Neurobiology and Pharmacology 207 241 .
Alexander Treiber, Ruben de Kanter, Catherine Roch, John Gatfield, Christoph Boss, Markus von Raumer, Benno Schindelholz, Clemens Muehlan, Joop van Gerven & Francois Jenck. (2017) The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. Journal of Pharmacology and Experimental Therapeutics 362:3, pages 489-503.
Crossref
Stephanie Born, David V. Gauvin, Suman Mukherjee & Richard Briscoe. (2017) Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regulatory Toxicology and Pharmacology 86, pages 181-192.
Crossref
Sydney Sullinger, Kelsie Bryand & Sarah Kerrigan. (2016) Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS). Journal of Analytical Toxicology.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.